Alembic Pharmaceuticals Limited has scheduled a Board of Directors meeting for Wednesday, 4th November, 2026. The primary agenda of the meeting is to consider and approve the company's unaudited financial results for the quarter and half year ended 30th September, 2026 (Q2 FY27).
Pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company was closed from 1st October, 2026. The trading window will re-open 48 hours after the declaration of the financial results to the stock exchanges.
The disclosure is signed by Chirag K. Shukla, Company Secretary of Alembic Pharmaceuticals Limited, and is addressed to both BSE Limited and National Stock Exchange of India Ltd.
Financial Impact
Financial results and specific impact not disclosed in this announcement. The meeting is scheduled to consider and approve the unaudited financial results.